Kenalog Injectable Product ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
70. Spinal stenosis
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03245671 (ClinicalTrials.gov) | December 2017 | 7/8/2017 | Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis | Particulate vs. Nonparticulate Epidural Steroid Injections for the Treatment of Symptomatic Unilateral Lumbar Foraminal Stenosis: a Prospective Double-blinded Randomized Study | Lumbar Spinal Stenosis | Drug: Kenalog Injectable Product;Drug: Decadron Phosphate, Injectable;Procedure: Epidural Steroid Injection | Hospital for Special Surgery, New York | NULL | Withdrawn | 18 Years | 90 Years | All | 0 | Phase 4 | United States |